Navigation Links
Prolong Pharmaceuticals Names Industry Veteran Glenn Kazo President
Date:9/28/2010

SOUTH PLAINFIELD, N.J., Sept. 28 /PRNewswire/ -- Prolong Pharmaceuticals today announced that industry veteran Glenn Kazo has assumed the title of President. Mr. Kazo has been consulting in various capacities with Prolong since 2007. He succeeds Prolong founder Dr. Abraham Abuchowski, who remains Chief Executive Officer.

"I have known Glenn for more than thirty years," said Dr. Abuchowski, who co-founded Enzon Pharmaceuticals in 1981 with Mr. Kazo. "I feel he is one of the greatest strategic minds in the biopharmaceutical world today, with a long history of successful experience behind him guiding small companies and startups. Through his consulting input and counsel, Glenn has already played a central role in Prolong's development, and as we move into the next phase of product development he will assume the major operational responsibilities for the company," said Dr. Abuchowski.

At Enzon, Kazo headed the steering committee for the blockbuster cancer drug PEG-Interferon. As Vice President of Sales and Marketing he built and managed a significant business development and licensing group and launched the company's first two drugs, Adagen® and Oncaspar® . Following Enzon, Kazo joined Focal, Inc., now a division of Genzyme, and helped take that company public. He later served as US General Manager and a member of the Board of Directors for the UK-listed public company XTL Biopharmaceuticals, and subsequently as Chief Business Office for Activbiotics a private VC backed anti-infective company.  Kazo has been responsible for raising over $300M in capital from international investors, including a leading role in three successful IPOs.

About Prolong Pharmaceuticals

Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing biopharmaceutical products targeting the treatment of anemia resulting from an oxygen deficiency. First founded in 2002 as a research company Prolong is focused on
'/>"/>

SOURCE Prolong Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromets Blinatumomab in Patients with Acute Lymphoblastic Leukemia
2. Trauma 411: Prolonged Surgery Should be Avoided in Certain Cases
3. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
4. Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer
5. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
6. Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients
7. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
8. Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma
9. Genasense Plus Chemotherapy Is Associated With Prolonged Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission
10. Treating Depression Prolongs Life for Older People with Diabetes
11. Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control & Sexual Function in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... Calif. and LONDON , Nov. ... and AstraZeneca (NYSE: AZN ) today announced that ... two doses of brodalumab in more than 1,800 patients with ... both Stelara ® (ustekinumab) and placebo at week 12. ... weight-based analysis group were each shown to be superior to ...
(Date:11/26/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 3, 2014 ... Helen Torley , President and Chief Executive Officer, will provide ... through the "Investors" section of Halozyme,s corporate website at ... 90 days following the event. To access the live webcast, ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... MINNEAPOLIS, Sept. 29 ProUroCare Medical Inc. (OTC Bulletin ... imaging products, today announced the signing of an agreement ... LP of Juno Beach, Fla.  The proceeds of the ... portfolio and to support scale-up activities associated with final ...
... PROSPECT, Ill., Sept. 29 Earlier this year, the National ... was introduced to the AWARxE campaign, which was created and ... the power of the campaign, NABP obtained the AWARxE program ... level. The Foundation was inspired to create ...
Cached Medicine Technology:UPDATE - ProUroCare Announces $3 Million Financing Agreement 2UPDATE - ProUroCare Announces $3 Million Financing Agreement 3NABP Purchases AWARxE Consumer Protection Program 2
(Date:11/27/2014)... Two international trainers and lecturers on the ... one person with significant needs but limited means obtain ... Mamaly Reshad of the Anacapa Dental Art Institute in ... devoted to helping dentist learn about using All-on-4™ dental ... devoted to helping a patient who has damaged or ...
(Date:11/27/2014)... 2014 Developers and plugin specialist of Final ... ProPip, taking FCPX to the next level. , “ProPip allows ... few clicks of a mouse,” said Christina Austin, CEO of ... users will appreciate.” , With ProPip users can show off ... truly endless. ProPip is great for commentaries, news casting, and ...
(Date:11/27/2014)... Philadelphia, PA (PRWEB) November 27, 2014 ... alongside volunteer Aria Health employees, prepared and donated ... to the Lutheran Settlement House , a non-profit, ... and families living in Philadelphia. The dinners were ... Settlement House Senior Center, and distributed to vulnerable ...
(Date:11/27/2014)... Delhi, India (PRWEB) November 27, 2014 ... has announced a search engine optimization service just ... small businesses or start-ups cannot afford costly search ... this service package, keeping their affordablity and requirements ... the service cost, but it has not compromised ...
(Date:11/27/2014)... 2014 VeloReality Inc. President Gary ... Life Videos (RLVs) of world-famous velo courses for the company's ... as other popular indoor velo trainers. Two dozen additional Real ... the end of November -- in time for the ... of rides in the VeloReality collection to over sixty. , ...
Breaking Medicine News(10 mins):Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Aria Health Prepares and Donates 200 Thanksgiving Dinners 2Health News:RBSEO Services Announces SEO Services at $99 Only 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 2Health News:Winter 2015 Weather Forecast Is Warm and Dry For VeloReality Riders With New RLV Offering 3
... Mich. Scientists at the University of Michigan Comprehensive Cancer ... cancer stem cells, the small number of cells in a ... that breast cancer stem cells are regulated by a type ... These cells are drawn from the bone marrow to the ...
... Controlling blood pressure is not only a medical challenge, ... required to strictly adhere to a treatment plan that ... the ideas of wellness and health are also powerful ... This is especially true in the African American ...
... recent study by Merikangas and colleagues published in the ... American Academy of Child and Adolescent Psychiatry (JAACAP) ... with severely impairing mental disorders ever receive treatment for ... one third of adolescents with any mental disorder received ...
... Heart disease is the leading cause of death for ... disease is more than just one disease; there are many ... blood pressure, diabetes or other causes. In lipotoxic cardiomyopathy, for ... cells. Obesity and high-fat diets are major risk factors for ...
... According to the World Health Organisation (WHO), an estimated 322,000 ... fire and in many of these cases death could have ... intervention, when major burn patients have insufficient skin left to ... skin has literally to be grown from the patient,s own ...
... Reporter , MONDAY, Jan. 17 (HealthDay News) -- Few ... measure up, according to new research. Dermatologists evaluated ... from the sun,s ultraviolet rays and found only a ... can penetrate glass. "The vast majority of the ...
Cached Medicine News:Health News:U-M researchers find indirect path to attack breast cancer stem cells 2Health News:Storytelling may help control blood pressure in African-Americans 2Health News:Adolescents with severe mental disorders have never received treatment 2Health News:A different path to fat-related heart disease 2Health News:Nanotech medicine 2Health News:Nanotech medicine 3Health News:Nanotech medicine 4Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 2Health News:Despite Claims, Many Daily Moisturizers Don't Shield Against Sun: Study 3
... Automated Microplate Washer is ... any laboratory. The unique ... a precise height adjustment ... digitally controlled aspiration- and ...
... washer MP-1200 is a compact and ... Its internal micropumps enable the system ... from all types of microtiter well. ... washed in rows of 8 wells ...
High-quality microplate washer with robot compatibility. It offers additional washing capacity, first-rate efficiency in high-throughput and research applications....
MultiWash Advantage is a versatile microplate washer engineered for reliability. It is designed for lab environments to help streamline their daily processes....
Medicine Products: